Pular para o conteúdo principal
Ranking Invest

RXRX - Recursion Pharmaceuticals, Inc.

Segmento: HealthcareRecursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Análise Ranking Invest

Valor de Mercado
$ 2.62 Bi
IVR
-0.27Índice proprietário de comparação relativa: -0,27.
IVR2
-0.64Leitura proprietária complementar: -64%.
MLL
-0.64Leitura proprietária complementar: -64%.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia proprietária baseada em dados financeiros públicos; fórmulas e valores intermediários são confidenciais.

Dados da Empresa

Patrimônio Líquido

$ 915.00 Mi

Dívida Líquida

-$ 545.68 Mi

L4T

-$ 518.88 Mi

MM4T

-1740.79%

Indicadores Básicos

ROE

-56.71%

Índices de Previsibilidade

Receita Líquida

F0.37

Lucro

B0.19

Margem

C0.40

Índices de Tendência

Receita Líquida

D1.04

Lucro

G-8.38

Margem

F-5.54

Índices de Endividamento

DIV/PAT

-0.60

DIV/L4T

1.05

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.